We report eight patients with ANKRD26-related thrombocytopenia-2 (ANKRD26-RT) with elevated bone marrow myeloblasts and dysmegakaryopoiesis, without somatic genetic abnormalities or progression to malignancy during long-term observation, findings which may constitute inherent ANKRD26-RT biology rather than progression to myeloid malignancy.

Subjects:
Hematopoiesis and Stem Cells
This content is only available as a PDF.
Copyright © 2025 American Society of Hematology
2025

Article PDF first page preview

First page of ANKRD26-related Thrombocytopenia 2 with a Baseline Increase in Blasts: Implications for Clinical Surveillance
You do not currently have access to this content.
Sign in via your Institution